NeuroMetrix (NASDAQ:NURO) Stock Price Crosses Above 200 Day Moving Average of $3.72

NeuroMetrix, Inc. (NASDAQ:NURO) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.72 and traded as high as $3.87. NeuroMetrix shares last traded at $3.86, with a volume of 8,622 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on NeuroMetrix in a research note on Thursday. They issued a “sell” rating on the stock.

NeuroMetrix Trading Down 0.8 %

The firm has a market cap of $7.42 million, a PE ratio of -0.59 and a beta of 2.16. The company has a 50-day simple moving average of $4.04 and a 200 day simple moving average of $3.72.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($1.67) earnings per share (EPS) for the quarter. The firm had revenue of $1.09 million for the quarter. NeuroMetrix had a negative return on equity of 39.85% and a negative net margin of 151.51%.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC purchased a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned approximately 2.80% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.